Introduction
Inflammatory bowel disease (IBD) is a family of chronic, idiopathic, relapsing, and tissue-destructive disorders, including Crohn's disease and ulcerative colitis, that has emerged as a worldwide public health challenge (1) . It is characterized by an abnormal immune response to the gut microflora in genetically susceptible individuals (2) . Despite advances in antitumor necrosis factor therapy, management of IBD in current clinical practice remains a daunting challenge (3) . Traditional therapies for IBD frequently result in multiple serious side effects and treatment resistance (4), highlighting the unmet need for alternative treatment options for IBD.
Mesenchymal stromal cells (MSCs) have recently shown great potential as a feasible and effective biological treatment for IBD (5) (6) (7) . The antiinflammatory and immunomodulatory activities of MSCs provide the theoretical grounds for MSC transplantation in IBD patients and as a potential novel cellular therapy for IBD (8) . Several preclinical studies demonstrate that implanted MSCs can home to the injured tissue and differentiate as functional cells in situ to replace damaged cells (9) . However, only a low percentage of implanted MSCs survive in vivo and engraft into injured tissues (10) . This strongly suggests that therapeutic effects mediated by MSCs might be attributed to their secretory pathways rather than their tissue-homing capacity. Indeed, the cell-free conditioned media of MSCs and the secretome of MSCs (containing extracellular vesicles and exosomes) afford beneficial effects in various diseases (11) (12) (13) . Despite numerous therapeutic vectors in the MSC secretome with antiinflammatory and immunosuppressive properties, no specific mediators have been identified as responsible for the beneficial effects of MSC-based therapy. Moreover, the risk of malignant transformation in human recipients, though not yet definitely confirmed, remains a critical problem impeding progress in the clinical translation of MSCs (5, 14) .
Conventional treatments for inflammatory bowel disease (IBD) have multiple potential side effects. Therefore, alternative treatments are desperately needed. This work demonstrated that systemic administration of exosomes from human bone marrow-derived mesenchymal stromal cells (MSC-Exos) substantially mitigated colitis in various models of IBD. MSC-Exos treatment downregulated inflammatory responses, maintained intestinal barrier integrity, and polarized M2b macrophages but did not favor intestinal fibrosis. Mechanistically, infused MSC-Exos acted mainly on colonic macrophages, and macrophages from colitic colons acquired obvious resistance to inflammatory restimulation when prepared from mice treated with MSC-Exos versus untreated mice. The beneficial effect of MSC-Exos was blocked by macrophage depletion. Also, the induction of IL-10 production from macrophages was partially involved in the beneficial effect of MSC-Exos. MSC-Exos were enriched in proteins involved in regulating multiple biological processes associated with the anticolitic benefit of MSC-Exos. Particularly, metallothionein-2 in MSC-Exos was required for the suppression of inflammatory responses. Taken together, MSC-Exos are critical regulators of inflammatory responses and may be promising candidates for IBD treatment.
In contrast, exosomes derived from MSCs (MSC-Exos), providing immune regulatory and tissue repair properties like MSCs, have recently emerged as a powerful component in the "secretory pathways" of MSCs and have aroused great enthusiasm (15) . Indeed, MSC-Exos evoke MSC-like protective effects in several diseases (16) (17) (18) . Mechanistically, Zhao et al. recently reported that exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarizing M2 macrophages (19) . In addition, Willis et al. demonstrated that MSC-Exos blunt hyperoxia-induced inflammation, partially by modulating the lung macrophage phenotype (11) . MSC-Exos-based cell-free treatment is more than a compensation for MSC-based treatment. MSC-Exos possess certain desirable features, including immunosilence, non-oncogenicity, high stability, cell-and tissue-specific homing, and no vascular obstructive propensity (20, 21) . Therefore, MSC-Exos offer a therapeutic advantage over MSC-based treatment, and it is of increasing interest to explore the potential roles of MSC-Exos in the management of IBD and their related mechanisms. Accordingly, we show that human bone marrow-derived MSC-Exos have protective effects on experimental colitis. Furthermore, we characterize the biological mechanism underlying the therapeutic value of MSC-Exos. Our findings present a potentially new therapeutic tool for the treatment of IBD.
Results
Isolation and purification of MSC-Exos. We isolated MSC-Exos from the supernatants of human bone marrow-derived MSCs. Before exosome extraction, flow cytometric analysis for MSC-related markers revealed that the MSCs were positive (≥95%) for CD105, CD90, and CD73 but were negative (≤2%) for CD45, CD79a, CD19, CD34, CD14, CD11b, and HLA-DR ( Figure 1A ). Propidium iodide (PI) and Annexin V analysis showed a good in vitro culture condition of the MSCs ( Figure 1B ), ruling out apoptotic bodies and random cell debris. Particle metrix (PMX) ( Figure 1C ) and transmission electron microscopy (TEM) (Figure 1D) confirmed their size distribution and shape were consistent with exosomes. Furthermore, Western blot revealed the exosomal identity markers TSG101 and CD9 ( Figure 1E ). Together, these data are indicative of successful isolation and purification of MSC-Exos.
MSC-Exos inhibit chemically induced colitis in mice. Next, we explored the potential protective effects of MSC-Exos in murine models of IBD induced by oral dextran sodium sulfate (DSS) administration or intrarectal infusion of 2,4,6-trinitrobenzenesulfonic acid solution (TNBS), both of which exhibit clinical, histopathological, and immunological phenotypes that closely parallel human IBD. By 7 days, mice receiving oral administration of 5% DSS displayed significantly elevated disease activity indexes (DAIs) ( Figure  2A ), with continuous body weight loss ( Figure 2B ). In striking contrast, intravenous injection of MSC-Exos reduced the clinical activity compared with that in mice treated with DSS plus phosphate-buffered saline (PBS) ( Figure 2 , A and B). Simultaneously, DSS administration led to significant colon shortenings, whereas MSC-Exos treatment significantly improved colonic inflammation, as shown by an increased colon length ( Figure 2C ). Histological examination indicated that MSC-Exos treatment maintained intestinal structural integrity and significantly reduced disruptions of the architecture, crypt loss, and infiltration of inflammatory cells, with lower histological scores compared with corresponding controls (Figure 2 , D and E). Moreover, MSC-Exos treatment afforded a comparable decrease in colonic myeloperoxidase (MPO) activity, suggesting less neutrophil infiltration ( Figure 2F ).
We further examined the anticolitic benefit of MSC-Exos in chronic and recurrent colitis. Oral treatment of 3% DSS in 2 cycles resulted in 2 peaks of colitis characterized by continuous weight loss, diarrhea, and bloody stools and causing ~80% mortality ( Figure 3 , A and B). MSC-Exos infusion at the first acute peak of colitis (day 7) markedly ameliorated the disease severity by day 9, as demonstrated by improved survival and stool consistency, less rectal bleeding, decreased colon shortening, reduced MPO activity, and amelioration of colon damage (Figure 3 , A-F). Noteworthily, mice with a single MSC-Exos injection at the first disease peak were endowed with clear resistance to disease activity during the second cycle of DSS treatment. A second MSC-Exos treatment at the second onset of disease (day 16) effectively prevented the recurrence of colitis ( Figure 3 , A-F).
The anticolitic benefit of MSC-Exos was not limited to DSS-induced colitis. Analogous to results using the DSS-induced colitis model, MSC-Exos were shown to be effective in inhibiting TNBSinduced colitis (Supplemental Figure 1 Extracts of MSC-Exos were exposed to Triton X-100 plus proteinase K (PK) or PK alone. MW, molecular weight.
Effect of MSC-Exos on mucosal inflammation and intestinal barrier integrity.
Dysregulation of inflammatory mediators has been well recognized in murine experimental colitis and in patients with IBD (22) . Thus, we determined the in vivo effect of MSC-Exos on the production of inflammatory cytokines mechanistically associated with IBD. Compared with untreated DSS-colitic mice, MSC-Exos administration decreased expression of several proinflammatory cytokines, including IFN-γ, IL-1β, IL-6, and TNF-α, whereas expression of the antiinflammatory cytokine IL-10 was significantly increased (Figure 4 , A-E).
Because it is a salient feature of IBD (23, 24) , we further investigated the effects of MSC-Exos on intestinal barrier dysfunction. DSS administration increased the serum levels of FITC-dextran, whereas MSC-Exos treatment significantly reduced the DSS-induced increase of intestinal permeability, as shown by significantly decreased levels of FITC-dextran ( Figure 4F ). An abnormal intestinal barrier could result in increased infiltration of intestinal microbes into intestinal lamina propria (23) . Indeed, DSS challenge increased the invasion of colonic tissues by microbes, and this was significantly reduced in mice treated with MSC-Exos ( Figure  4G ). In accordance with that, DSS administration decreased the mRNA levels of antimicrobial peptides in colons, including lysozyme 1 (Lyz1); defensin, alpha, 20 (Defa20); defensin, alpha, 29 (Defa29); and angiogenin, ribonuclease A family, member 4 (Ang4), whereas MSC-Exos treatment reversed these trends ( Figure 4H ). Together, these data indicated that MSC-Exos contribute to the maintenance of gut homeostasis.
The anticolitic benefit of MSC-Exos is macrophage dependent. Subsequently, to elucidate the cell type targeted by implanted MSC-Exos in colitis, we intravenously infused PKH26-labeled MSC-Exos into DSS-colitic mice. By analyzing the frequency of exosome-positive cells (PKH26 + ) in a million cells from each colon, we found that MSC-Exos were recruited by the inflamed colon but not by noninflamed intestine ( Figure 5 , A and B). In addition, about 50% of PKH26 + cells were F4/80 + CD11b + as analyzed by flow cytometry, a phenotype consistent with colonic macrophages ( Figure 5 , A and C). In contrast, labeled MSC-Exos were not efficiently engulfed by colonic macrophages in DSS-untreated mice ( Figure 5 , A-C). Together, these data suggest that macrophages are the predominant cell type taking up MSC-Exos in colitis and are probably responsible for the anticolitic benefit of MSC-Exos. To substantiate this supposition, we deleted colonic macrophages in mice with intraperitoneal injection of clodronate liposomes (Clod-lipos) (PBS liposomes [PBS-lipos] as negative controls). As anticipated, administration of Clod-lipos effectively deleted colonic macrophages (Supplemental Figure 3, A and B ). MSC-Exos were no longer effective in DSS-colitic mice lacking macrophages, providing no significant improvement in DAI, colon length, histopathological examination, and colonic MPO activity ( Figure 5 , D-G). Taken together, these findings indicate that colonic macrophages are essential for the anticolitic benefit of MSC-Exos treatment.
MSC-Exos ameliorate mucosal inflammation by remodeling macrophage phenotypes. Colonic macrophagemediated mucosal inflammatory responses play a central role in the onset and severity of IBD. To delineate the mechanism of the anticolitic benefit of MSC-Exos, we investigated the in vivo effects of MSC-Exos on colonic macrophages. Despite no significant change in the percentage of F4/80 + CD11b + cells in the lamina propria of colons, the expression levels of CD206 and arginase-1 in colonic macrophages were significantly elevated upon MSC-Exos treatment ( Figure 6 , A-D). As anticipated, the colonic expression of markers indicative of M2 macrophages was also significantly upregulated upon transfer of MSC-Exos (Supplemental Figure 4 , A and B). More excitingly, macrophages isolated from mice treated with MSC-Exos produced less IL-1β, IL-6, and TNF-α but more IL-10 on ex vivo culture ( Figure 6E ), revealing that the reduction of mucosal inflammatory responses upon MSC-Exos treatment might be a consequence of direct action on colonic macrophages. Importantly, macrophages from colitic colons acquired obvious resistance to LPS restimulation when prepared from mice treated with MSC-Exos versus untreated mice ( Figure 6E ). Altogether, these data suggest that MSC-Exos attenuate mucosal inflammation by polarizing M2b macrophages. The effect of MSC-Exos on intestinal fibrosis was also analyzed. ELISAs (Supplemental Figure 4C ) and reverse transcription PCR gels (Supplemental Figure 4D ) revealed no significant differences in the levels of collagen in MSC-Exos-treated mice compared to controls. As shown by Masson's trichrome staining, DSS administration led to increased collagen in the colons of chronic DSS-colitic mice, whereas MSC-Exos treatment did not result in increased colonic collagen (Supplemental Figure 4E ). Collectively, these data indicate that MSC-Exos treatment does not favor intestinal fibrosis.
Macrophage-derived IL-10 is key for the beneficial effect of MSC-Exos. Because MSC-Exos treatment increased colonic expression of the immunosuppressive cytokine IL-10 ( Figure 4E) , we asked whether IL-10 is important for the anticolitic benefit of MSC-Exos in DSS-colitic mice. Administration of an antibody against IL-10 in mice treated with MSC-Exos and 5% DSS yielded intermediate DAI and colonic MPO activity compared with time-matched mice treated with DSS and MSC-Exos plus DSS ( Figure 7A) . Therefore, IL-10 is an important component of the anticolitic benefit of MSC-Exos. We next set out to understand the source of IL-10 elevation in colons upon MSC-Exos treatment. It is unlikely that the injected MSC-Exos were the source of the elevated IL-10 because the protein cargo contained in MSC-Exos did not include IL-10 as determined by Western blot and ELISA (data not shown). Large amounts of IL-10 are produced mainly by type 2 helper T (Th2) cells, T regulatory cells, and macrophages (25, 26) . To assess the involvement of T cells in elevating IL-10, we isolated CD4 + T cells from the mesenteric lymph nodes (MLNs) of DSS-colitic mice. On ex vivo culture, CD4 + T cells with MSC-Exos treatment did not upregulate IL-10 expression, even after restimulation with phytohemagglutinin (PHA) ( Figure 7B ). In addition, the Th1 and Th2 cell profile of CD4 + T cells was not significantly influenced upon MSC-Exos treatment ( Figure 7C and Supplemental Figure 4F ). Macrophage depletion impaired the anticolitic effect of MSC-Exos, supporting the notion that macrophages might be the source of the elevated IL-10 in colons upon MSC-Exos treatment. Further supporting this hypothesis, F4/80 + macrophages isolated from mice treated with MSC-Exos produced more IL-10 on ex vivo culture ( Figure 6E ). Together, these data suggest that the elevated IL-10 in colons upon MSC-Exos treatment is at least partially derived from colonic macrophages and is probably not associated with Th2 or T regulatory cells.
To further support the involvement of macrophage-derived IL-10 in the beneficial effects of MSC-Exos, we analyzed the regulatory potential of macrophages educated by MSC-Exos on CD4 + T cells. In contrast to control macrophages, those educated by MSC-Exos and IL-4 significantly inhibited the proliferation of CD4 + T cells at ratios as low as 1:10 (Figure 7 , E and F) and significantly suppressed the production of the inflammatory cytokines TNF-α and IFN-γ ( Figure 7, G and H) . The IL-10 blockade partially reversed the inhibitory activity of macrophages educated by MSC-Exos on activation of CD4 + T cells (Figure 7 , D-H).
MSC-Exos inhibit the inflammatory response of macrophages via transporting metallothionein-2. To understand the molecular basis mediating the effects of MSC-Exos, we performed proteomic analysis to analyze the protein expression profiles in MSC-Exos and the corresponding supernatants from their parent MSCs (PRIDE Archive, Project PXD015386). We identified 1315 protein groups, among which 992 proteins were quantified. All the identified proteins were biologically interpreted, and their involved biological processes were explored. MSC-Exos were enriched in proteins involved in regulating multiple biological processes related to the anticolitic benefit of MSC-Exos, such as immune modulation, cytokine secretion, NF-κB signaling pathway, acute inflammatory response regulation, and collagen catabolic process ( Figure 8A ). We selected 389 differentially expressed proteins by volcano plot filtering between MSC-Exos and the corresponding supernatants (fold change ≥ 2 and P ≤ 0.05) ( Figure 8B ). Among them, metallothionein-2, a high conservative protein between Homo sapiens and Mus musculus, was the most highly upregulated by more than 9-fold in MSC-Exos compared with the supernatants (Figure 8B ). ELISAs confirmed the significant enrichment of metallothionein-2 in MSC-Exos ( Figure 8C ), and metallothionein-2 appeared to be uniquely upregulated in MSC-Exos (Supplemental Figure 5A ). In addition, the presence of metallothionein-2 in exosomes was necessary to have uptake into macrophages (Supplemental Figure 5B ), which at least partly explained why free metallothionein-2 had no activity on the polarization of macrophages (Supplemental Figure 5, C and D) .
To investigate the role of metallothionein-2 in the beneficial effect of MSC-Exos in macrophages, 3 siRNAs (siMT2A #1 , siMT2A #2 , and siMT2A #3 ) were used to knock down metallothionein-2 expression in MSC-Exos. The inhibitory efficiency of these siRNAs was tested by ELISAs. Results from ELISAs showed the downregulation of metallothionein-2 in MSC-Exos from MT2A-silenced MSCs (MSC-Exos siMT2A#2 ) ( Figure 8C ). As expected, the reduction of metallothionein-2 in MSC-Exos interfered with the antiinflammatory effects of MSC-Exos both in vitro ( Figure 8D ) and in vivo (Supplemental Figure 6 , A-C). A previous study revealed that metallothionein-2 could attenuate NF-κB activity (27) . Indeed, treatment with MSC-Exos dose-dependently resulted in reduced level of phosphorylated IκBα in macrophages but increased total IκBα level in both protein and mRNA ( Figure 8E and Supplemental Figure 6D) . A reduction of NF-κB p65 subunit nuclear translocation was also observed ( Figure 8E ). Furthermore, knockdown of metallothionein-2 significantly reversed the increase of IκBα mRNA levels induced by MSC-Exos (Supplemental Figure 6D ). As expected, the inhibitory effect of MSC-Exos on NF-κB activation was compromised as well ( Figure 8E ). It has been reported that metallothionein-2 could enhance IκBα transcription via interacting with myeloid zinc finger 1 (MZF1), which directly bound to IκBα promoter (27) . In agreement with this, MSC-Exos failed to enhance IκBα transcription in macrophages when MZF1 was knocked down using siRNA (Supplemental Figure 6E) , implying a vital role of MZF1 on the increase of IκBα transcription. Taken together, these findings revealed that metallothionein-2 transmitted by MSC-Exos was likely to suppress NF-κB activation via MZF1 by enhancing IκBα transcription and inhibiting the phosphorylation of IκBα.
Discussion
Current available medical therapeutic options for IBD have not been able to completely halt the progression of IBD or to change its natural history. Therefore, designing optimal therapeutic strategies has been the subject of intense investigation. We propose a new therapeutic tool for IBD treatment in murine preclinical models using MSC-Exos, pivoting from MSC-based cell transplantation to cell-free therapeutics. Systemic infusion of MSC-Exos at the disease onset was sufficient to reduce the severity of acute colitis, and administration of MSC-Exos in mice significantly ameliorated the severity of chronic colitis. An initial MSC-Exos infusion also prevented the recurrence of the disease after subsequent DSS administration. In addition, the anticolitic effect of MSC-Exos is mouse strain independent. MSC-Exos treatment efficiently ameliorated colitis in both C57BL/6 and BALB/c strains. These results are potentially relevant with respect to disease intervention.
A critical concern is whether the use of human exosomes in animal models, a xenogeneic material systemic administration, would elicit immune rejection. Theoretically, exosomes are non-immune rejective (20) . Indeed, when using human exosomes in animal models, numerous studies have revealed significant therapeutic effects in several diseases, and no immune rejection to date has been observed in the xenogeneic system (11, 16, 20, 28) . In line with the previous reports (11, 16, 20, 28) , no significant immunological rejection was detected when MSC-Exos were administrated to xenogeneic hosts in this study (Supplemental Figure 7 , A-D). Additionally, class I and II major histocompatibility complex, key mediators of potential immune rejection, were absent on MSC-Exos as determined by Western blot (data not shown). These findings suggest that the immunosuppressive action of MSC-Exos is not major histocompatibility complex restricted and that the infused MSC-Exos are immunotolerated by the host, which is convenient for a future clinical application of MSC-Exos in IBD.
Dysregulation of inflammatory mediators and disruption of intestinal barrier integrity in IBD patients and in experimental colitis often interact in a positive feedback loop, together forming a vicious cycle (29) (30) (31) . MSC-Exos treatment could serve dual roles to break this cycle, by reducing a panel of inflammatory mediators and maintaining intestinal homeostasis. Regarding the potential mechanisms, it is interesting that infused MSC-Exos are mainly targeted to macrophages in DSS-elicited inflamed colons. In addition, MSC-Exos treatment increases markers indicative of M2 macrophages in the colons of DSS-colitic mice. Therefore, intestinal macrophages may mediate the anticolitic benefit of MSC-Exos. Indeed, this benefit of MSC-Exos was abolished in macrophage-depleted mice, which further supports our hypothesis.
Subsequently, we sought to understand why pretreatment with MSC-Exos failed to exert prophylactic effects on experimental colitis. By in vivo trafficking MSC-Exos, we found that noninflamed intestines that failed to recruit infused MSC-Exos and macrophages made up only 5%-10% of all the cells that incorporated peripheral blood monocytes treated with 30 μg/mL MSC-Exos or MSC-Exos siMOCK or MSC-Exos siMT2A#2 for 2 days, then stimulated with LPS (100 ng/mL) during the last 4 hours, with 18S rRNA as a housekeeping gene. n = 3 independent experiments. (E) Representative immunoblot for phosphorylated IκBα (p-IκBα), total IκBα (t-IκBα), and p65 subunit from whole-cell, nuclear, and cytoplasmic extracts in macrophages that were treated for 2 days, with the indicated dose of MSC-Exos from MSCs that were untransfected (Un), mock transfected (Mock-si), or transfected with MT2A-siRNAs (MT2A-si). Three independent experiments were performed and yielded similar results. β-actin and Lamin A served as loading controls. **P ≤ 0.01; ***P ≤ 0.001; ns indicates P > 0.05, by Kruskal-Wallis test (C and D).
MSC-Exos, indicating an equal distribution in the body. This may provide a straightforward biological explanation for the failure of pretreatment. Furthermore, infused MSC-Exos were detected and maintained in the inflamed colons for no less than 5 days after injection, a time lag long enough to exert long-lasting protective actions. In striking contrast, the presence of transplanted MSCs decreased dramatically in the recipient at 2 days after infusion (32) . This may endow MSC-Exos with a therapeutic advantage over MSCs. Noteworthy for MSC-Exos treatment is the possibility that the increase of M2 macrophage activity may lead to intestinal fibrosis, a severe and distressing complication of IBD (33, 34) . On this front, although our data negate that MSC-Exos treatment favors intestinal fibrosis, optimization research establishing an ideal model for experimental research of intestinal fibrosis should be performed to monitor the possibility of fibrosis after MSC-Exos transplantation.
Regulatory cytokines can inhibit murine experimental colitis (35, 36) . We found that colonic levels of IL-10 were substantially increased in mice treated with DSS plus MSC-Exos compared with DSS plus PBStreated control mice. Moreover, protection from colitis in MSC-Exos-treated mice was dependent on regulatory cytokine IL-10 because administration of MSC-Exos was less effective in DSS-colitic mice treated with mAb against IL-10. Subsets of T cells are a possible source of the elevated IL-10 (25, 26) . However, we observed that MSC-Exos treatment failed to increase the production of IL-10 on ex vivo culture, which preliminarily negates the hypothesis that subsets of T cells produce the elevated IL-10. In contrast, macrophages isolated from treated DSS-colitic mice produced substantially higher levels of IL-10 than those from untreated mice. These results suggest that colonic macrophages are at least 1 source of the increased IL-10 and reinforce the notion that macrophage-derived IL-10 is a critical mediator of the anticolitic benefit of MSC-Exos. Nevertheless, macrophage-derived IL-7 may be involved in ameliorating murine experimental colitis when treated with exosomes from human umbilical cord MSCs (37) . Therefore, we cannot exclude the possibility that additional factors after transfer of MSC-Exos in DSS-colitic mice may also play a role in protection from colitis because neutralization of IL-10 alone did not fully block the anticolitic effect of MSC-Exos.
Infiltration and activation of neutrophils in the intestinal mucosa are essential to the pathogenesis of IBD (38, 39) . Neutrophils migrate into the lamina propria of DSS-induced colitis, where they eliminate invading bacteria using MPO, concomitantly eliciting oxidative organ damage, an undesirable effect of MPO (40) (41) (42) . As such, MPO activity has become a widely accepted indicator of neutrophil activity. We observed that colonic MPO activity was significantly decreased in DSS-colitic mice treated with MSC-Exos, indicating that MSC-Exos treatment inhibits neutrophil invasion. IL-10 is a potent regulator of the migration and invasion of neutrophils. It is possible that the decreased MPO activity was a consequence of the elevated IL-10 in MSC-Exos-treated DSS-colitic mice. This was primitively validated by the fact that the neutralizing anti-IL-10 antibody reversed the reduction of colonic MPO activity following intravenous injection of MSC-Exos.
To assess the molecular basis mediating the effects of MSC-Exos, we performed a proteomic analysis of MSC-Exos, which indicated that immunosuppressive or antiinflammatory activity is a salient feature of MSC-Exos. Specifically, our findings revealed that levels of metallothionein-2 were extremely high in MSC-Exos. When metallothionein-2 was inhibited in the parent MSCs, the antiinflammatory effects of MSC-Exos on macrophages in vitro were significantly suppressed. NF-κB signaling is a downstream target of metallothionein-2 (27, 43) . Consistent with this, MSC-Exos induced a significant decrease in NF-κB activity, whereas this effect was compromised when the expression of metallothionein-2 in MSC-Exos was inhibited. Our findings suggest that metallothionein-2 in MSC-Exos acts as a critical negative regulator of the inflammatory response in macrophages. Of note, metallothionein-2 possesses high conservation between Homo sapiens and Mus musculus, indicating that human metallothionein-2 in MSC-Exos could work in mice. However, the antiinflammatory effects of MSC-Exos were not fully blocked by metallothionein-2 inhibition both in vitro and in vivo, suggesting that other components of MSC-Exos might also serve as active mediators.
Metallothionein-2, a member of the metallothionein family, is a low-molecular weight, cysteine-rich protein (44, 45) . Metallothioneins are present in multiple tissues and mainly consist of 4 groups: metallothionein-1A, metallothionein-2, metallothionein-3, and metallothionein-4. It has been reported that metallothionein-2 serves as a critical regulator of numerous cell activities, including differentiation, apoptosis, autophagy, immune response, carcinogenesis, and drug resistance (28, (46) (47) (48) (49) (50) . The effects of metallothionein-2 on pathophysiological processes, particularly inflammation, are subjects of many studies (51) . A study by Liu et al. showed that metallothionein-2 knockdown increased LPS-induced IL-6 production in endothelial cells (49) , indicating a protective role against inflammatory responses. Takano and colleagues demonstrated that transgenic mice with metallothionein overexpression were more resistant to neutrophilic lung inflammation and lung edema induced by intratracheal challenge with LPS (52). Metallothionein-2 has also been found to be a critical regulator of NF-κB signaling because its upregulation attenuates NF-κB activity in tumor cells, keloid fibroblastic cells, as well as cardiomyocyte cells (53) (54) (55) (56) . In line with these studies, our results demonstrated the antiinflammatory effects of metallothionein-2 on both macrophages and mouse colitis models. It is noteworthy that the presence of this protein in exosomes may offer a therapeutic advantage over its free form because free proteins are unlikely to interact with cells or have uptake into cells (57, 58) . Furthermore, the role of metallothionein-2 might not be unique for colitis. In contrast, it should be applicable to other disorders, especially those with macrophages involved in the pathogenesis.
In summary, we propose a novel therapeutic strategy for the treatment of IBD based on the use of MSC-Exos, and of obvious therapeutic significance is that generation of a clinically effective dosage of MSC-Exos under good manufacturing practice is feasible and rapid (59) and that MSC-Exos can be stored frozen and ready to use in any clinical scenario. Once the benefits and risks related to the infusion of MSC-Exos are well evaluated, this cell-free therapy will provide new perspectives for IBD therapy.
Methods
Detailed procedures are provided in Supplemental Methods.
Exosome preparation. Exosomes were isolated from the supernatant of human bone marrowderived MSCs (herein referred to as MSC-Exos) by standard ultracentrifugation methods, as previously described (60) .
Induction of experimental colitis. IBD mouse models of experimental colitis were induced by oral DSS administration and by intrarectal infusion of TNBS. Exosomes were intravenously administrated to mice at the indicated time, and macrophage depletion using Clod-lipos was performed as previously described (61) (62) (63) . Mice were sacrificed at the indicated time, the entire colon was removed from the cecum to the anus, and colon length was measured as an indirect marker of inflammation. Colon segments were processed for histopathological or flow cytometry analysis or frozen in liquid nitrogen for protein and RNA extraction. Cytokine and MPO activities were measured according to the manufacturer's protocol. To track injected exosomes in vivo, MSC-Exos were labeled with PKH26 before infusion and analyzed via flow cytometry analysis.
Histopathological evaluation. Collected colon samples were fixed with 10% formalin and embedded in paraffin. After paraffin embedding, 5-μm thick sections were made and stained with HE. Histopathology scores were determined in colonic sections by 2 blinded trained pathologists (unaware of group identity), with a combined score for inflammatory cell infiltration (score, 0-3) and tissue injury (score, 0-3), according to our previous report (2) .
Isolation of macrophages from the lamina propria of mouse colons. Colonic macrophages were isolated using immunomagnetic separation with anti-F4/80 mAb (Miltenyi Biotec), determined by F4/80 + and CD11b + staining, and then used for the analysis of cytokine secretion.
Measurement of colonic tissue bacterial load. Colon tissues were collected and homogenized in sterile physiological saline. After centrifuging at 13,000 g for 10 minutes at 4°C to remove insoluble material, 100 μL of the tissue lysate supernatants containing 100 μg of colonic tissue extracts was plated in duplicate on blood agar plates and incubated at 37°C for 2 days. Bacterial loads were defined as the average number of bacterial colony-forming units per gram of colonic tissues (wet weight).
Statistics. Results from the duplicate reproducible experiments were combined for statistical analysis. SPSS16.0 was used for all the statistical analyses. Data represent mean ± SD. To determine the statistical significance, 2-tailed Student's t test or 1-way ANOVA was applied for the continuous variables with normal distributions, whereas Mann-Whitney or Kruskal-Wallis test was used when distributions were skewed. P ≤ 0.05 was considered statistically significant.
Study approval. All samples from human tissues were collected with written informed consent from donors, and all procedures were performed with the approval of the Institutional Review Board of The Sixth Affiliated Hospital of Sun Yat-sen University. Animal experiments were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University and conformed to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (National Academies Press, 2011) in China.
